• Publications
  • Influence
Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease.
Mild Alzheimer's disease (AD) is often difficult to differentiate from mild cognitive impairment (MCI) or non-AD dementias. A multitude of diagnostic biomarkers and advanced imaging strategies haveExpand
  • 186
  • 16
  • PDF
Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)
Migraine is a disabling neurological disease that affects 14.7 % of Europeans. Studies evaluating the economic impact of migraine are complex to conduct adequately and with time become outdated asExpand
  • 200
  • 10
The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
ObjectiveThe Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) has been shown to have good psychometric performance in measuring headache impact in migraine patients, but itsExpand
  • 41
  • 6
The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK
Abstract Background: Although chronic migraine is associated with substantial disability and costs, few treatments have been shown to be effective. OnabotulinumtoxinA (Botox, Allergan Inc., Irvine,Expand
  • 36
  • 5
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
BACKGROUND Multiple myeloma is a progressive cancer for which there is no cure. Despite treatment, almost all patients eventually experience periods of disease relapse and remission. With theExpand
  • 30
  • 4
Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine
BackgroundThe Headache Impact Test (HIT)-6 was developed and has been validated in patients with various types of headache. The objective of this study was to report the psychometric properties ofExpand
  • 64
  • 3
Systematic review of migraine prophylaxis adherence and persistence.
BACKGROUND Migraine is a common neurological disease affecting 12% of Americans and millions worldwide. Medication adherence has been studied extensively in many chronic conditions, with poorExpand
  • 134
  • 2
  • PDF
Adherence with Migraine Prophylaxis in Clinical Practice
Objective:  To characterize adherence with antidepressants, antiepileptic drugs, and beta blockers as prophylaxis against migraine in typical clinical practice.
  • 60
  • 2
Treatment Persistence and Switching in Triptan Users: A Systematic Literature Review
To conduct a systematic review to evaluate persistence to and switching of triptan therapy for the acute treatment of migraine.
  • 24
  • 2
Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
BACKGROUND Multiple myeloma is an incurable B-cell malignancy with a natural history that involves alternating periods of remission and subsequent relapse. For relapsed and/or refractory multipleExpand
  • 4
  • 2